Denosumab for Smoldering Multiple Myeloma
Phase 2
Completed
NCT03839459
| Condition | Smoldering Multiple Myeloma |
|---|
| Phase | Phase 2 |
|---|
| Sponsor | University of Rochester |
|---|
| Status | Completed |
|---|
| Enrollment | 20 participants |
|---|
| Interventions | Denosumab |
|---|
| Start date | Apr 19, 2019 |
|---|
| Completion date | Sep 16, 2022 |
|---|
| Results posted | Feb 15, 2023 |
|---|
Summary
This study will assess the safety and tolerability of denosumab in smoldering multiple myeloma subjects as well to see if denosumab can reduce subjects' risk of getting multiple myeloma.
Proportion of Subjects With a Downgraded Risk of Progression of Smoldering Multiple Myeloma if the Risk Category Decreases.
1 year · proportion of participants
| Denosumab | 0 proportion of participants |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.